RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: HIV Infections, PLWH, ART, Acute HIV Infection
In brief
This is a phase I, randomized, double-blind, placebo-controlled clinical trial to investigate the safety of VRC07-523LS and PGDM1400LS in combination with ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62 prime, MVA.tHIVconsv4 and A244d11gp120/ALFQ vaccination, and the impact on viral load setpoint during analytic treatment interruption (ATI) in people living with human immunodeficiency virus-1 (HIV-1, PLWH) who have initiated or will initiate antiretroviral therapy (ART) during acute HIV-1 infection (AHI).
Key facts
- Study ID
- NCT06484335
- Run by
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- People needed
- 48
- Starts
- 2025-03-27
- Expected to finish
- 2027-08-01
- Last updated by the study team
- 2025-09-16
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Faculty of Medicine, Chulalongkorn University/ King Chulalongkorn Memorial Hospital — Pathum Wan, Bangkok, Thailand (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.